Patient Subgroups

Cross-source consensus on Patient Subgroups from 1 sources and 3 claims.

1 sources · 3 claims

Comparisons

EV-Pem had its best subgroup cost-effectiveness result in patients with high PD-L1 expression. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
EV-Pem performed worst in cisplatin-eligible patients because its incremental survival benefit was smallest relative to standard chemotherapy. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
Subgroup ICERs were estimated using stratified OS and PFS curves for PD-L1 expression and cisplatin eligibility. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom